Tango Therapeutics Inc. 宣布,其药物组合Vopimetostat与Daraxonrasib将进入针对MTAP缺失型胰腺癌的第三阶段临床研究。这一进展标志着该公司在精准肿瘤学领域的重要一步,旨在为这种特定基因亚型的胰腺癌患者探索新的治疗可能性。
Tango Therapeutics Inc. 宣布,其药物组合Vopimetostat与Daraxonrasib将进入针对MTAP缺失型胰腺癌的第三阶段临床研究。这一进展标志着该公司在精准肿瘤学领域的重要一步,旨在为这种特定基因亚型的胰腺癌患者探索新的治疗可能性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.